Clinuvel easily the most shorted Biotech despite peerless...

Clinuvel easily the most shorted Biotech despite peerless financials, market monopoly and growing profits, EPS, and cash year after year and advancing their blockbuster phase 3 trial at the same time. Less than 3 years ago Mesoblast was the most shorted biotech but today they are hundreds of percent higher and remaining short sellers got severely burnt recently (about 3.33%), it's going to be interesting if they get smashed again by shorters now as they are a heavily diluted company and yet to prove they can make a dollar unlike Clinuvel who are just printing cash at an ever increasing rate (interestingly shorts have ticked up to 3.53% at MSB). Does anyone want to provide an estimate of the profits CUV will pump out if Vitiligo is approved with a drug that is ALREADY FDA approved and safe? IMO it will exceed the $25 Billion PME current financials easily just look at management statements.... Vitiligo Phase 3 running, slated for FDA submission 2026, drug already FDA approved and SAFE for EPP. Vitiligo TAM mentioned $4.5 BILLION USD and 9% penetration years 1-2 giving $490 - $570 Million USD. Pearl Grimes on Clinuvel Board, the drug has unheard of 95% patient retention and recruitment must be getting close to completion?

Mesoblast had a great run up on anticipation of FDA approval, will Clinuvel follow that path also as recent available evidence shows nearly all the share price action here is manipulation and short selling? Shorting a company at sky high valuations can make sense, but even at MSB they got that wrong, but short selling for the lowest price possible is a different game, potentially a takeover, but definitely a very risky game. Mesoblast now at nearly $4 Billion valuation! yet to make a buck and heavily diluted but they now are set up to prove what they can do, Clinuvel valued about 10 times less (take out $200 Million cold hard cash) when they are the best financially performing small Biotech and showing how to print cash. CUV to take their run at the big blockbuster indication and are positioned in that respect just like MSB were just under 3 years ago as the most shorted Biotech except they ALREADY have an FDA approval for the drug which is targeting the blockbuster. Will Clinuvel do a Mesoblast now and jump hundreds of percent higher if they achieve that approval? Or just in anticipation? They have proven they can print cash on just a small indication, what would a blockbuster indication do to already great financials? Interesting year coming up.

All IMO DYOR